Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Precision medicine in lung cancer: the battle continues.

Literature DB >> 28066565

Precision medicine in lung cancer: the battle continues.

Saiama N Waqar¹, Daniel Morgensztern¹.

Abstract

Entities: Disease

Year: 2016 PMID： 28066565 PMCID： PMC5179408 DOI： 10.21037/jtd.2016.11.46

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

23 in total

1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors: Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal: Lancet Oncol Date: 2012-01-26 Impact factor: 41.316

Review 2. Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Authors: D Ross Camidge; William Pao; Lecia V Sequist
Journal: Nat Rev Clin Oncol Date: 2014-07-01 Impact factor: 66.675

3. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.

Authors: Lynette M Sholl; Dara L Aisner; Marileila Varella-Garcia; Lynne D Berry; Dora Dias-Santagata; Ignacio I Wistuba; Heidi Chen; Junya Fujimoto; Kelly Kugler; Wilbur A Franklin; A John Iafrate; Marc Ladanyi; Mark G Kris; Bruce E Johnson; Paul A Bunn; John D Minna; David J Kwiatkowski
Journal: J Thorac Oncol Date: 2015-05 Impact factor: 15.609

4. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo
Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544

5. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors: Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal: N Engl J Med Date: 2014-12-04 Impact factor: 91.245

6. Screening for epidermal growth factor receptor mutations in lung cancer.

Authors: Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal: N Engl J Med Date: 2009-08-19 Impact factor: 91.245

7. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors: Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544

8. The BATTLE trial: personalizing therapy for lung cancer.

Authors: Edward S Kim; Roy S Herbst; Ignacio I Wistuba; J Jack Lee; George R Blumenschein; Anne Tsao; David J Stewart; Marshall E Hicks; Jeremy Erasmus; Sanjay Gupta; Christine M Alden; Suyu Liu; Ximing Tang; Fadlo R Khuri; Hai T Tran; Bruce E Johnson; John V Heymach; Li Mao; Frank Fossella; Merrill S Kies; Vassiliki Papadimitrakopoulou; Suzanne E Davis; Scott M Lippman; Waun K Hong
Journal: Cancer Discov Date: 2011-06-01 Impact factor: 39.397

9. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Authors: Alice T Shaw; Leena Gandhi; Shirish Gadgeel; Gregory J Riely; Jeremy Cetnar; Howard West; D Ross Camidge; Mark A Socinski; Alberto Chiappori; Tarek Mekhail; Bo H Chao; Hossein Borghaei; Kathryn A Gold; Ali Zeaiter; Walter Bordogna; Bogdana Balas; Oscar Puig; Volkmar Henschel; Sai-Hong Ignatius Ou
Journal: Lancet Oncol Date: 2015-12-19 Impact factor: 41.316

10. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors: Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal: Lancet Oncol Date: 2016-03-11 Impact factor: 41.316

1 in total

1. Involvement of glycogen debranching enzyme in bladder cancer.

Authors: Benjamin Weinhaus; Sunny Guin
Journal: Biomed Rep Date: 2017-05-09

1 in total